Regional anesthesia

Analgesic efficacy of erector spinae plane block versus paravertebral block in lung surgeries—A non‐inferiority randomised controlled trial

Acta Anaesthesiol ScandPublished Randomised controlled trial

Authors' conclusion

This trial demonstrated that a continuous erector spinae plane block was not non-inferior to a continuous paravertebral block for analgesia after lung surgery but resulted in higher levels of postoperative pain and opioid consumption.

Study context

Population
Patients undergoing unilateral lung surgeryenrolled at interim analysis
Participants
120 patients
Comparison
Continuous Erector Spinae Plane Block (ESPB) vs continuous paravertebral block (PVB) at T5
Primary endpoint
Pain on numerical rating scale (NRS) (interaction of three measures); NRS ≥ 7 = analgesia failure; non-inferiority margin 10%
Follow-up
24 h postoperatively
Methodological detailsnon-inferiority, active-controlled, blinded for patients and assessors, interim analysis, Terminated at interim analysis
  • Non-inferiority
  • Active-controlled
  • Blinded for patients and assessors
  • Interim analysis
  • Terminated at interim analysis

Primary result

Mean NRS over 24 h · 24 h

Difference

−0.67

95% CI −1.29 to −0.05

P = 0.02

By group

ESPB

4.6

mean · SD 3.2

PVB

3.9

mean · SD 2.9

ESPB vs PVB
difference −0.67 (95% CI −1.29 to −0.05); P = 0.02

Non-inferiority margin 10 as printed, not drawn

As reported in the abstract

Further findings

OutcomeP value
NRS analgesia failure · 24 hHigher in ESPBP < 0.01
Postoperative opioid consumption · 24 hMore in ESPBP = 0.01

Patient satisfaction

No difference between groups

Original publication

Analgesic efficacy of erector spinae plane block versus paravertebral block in lung surgeries—A non‐inferiority randomised controlled trial. Acta Anaesthesiol Scand. Published 30 August 2023. doi:10.1111/aas.14325

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.